CALY-002 is under clinical development by Calypso Biotech and currently in Phase I for Eosinophilic Esophagitis. According to GlobalData, Phase I drugs for Eosinophilic Esophagitis have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CALY-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CALY-002 is under development for the treatment of eosinophilic esophagitis, celiac disease and unspecified dermatological disorders. It is a fully-humanized monoclonal antibody also administered intravenously. It acts by targeting IL-15. It was also under development for other unspecified diseases and auto immune diseases.
It was also under development for autoimmune disorders.
Calypso Biotech overview
Calypso Biotech (Calypso), a spin-off from Merck Serono, is a biopharmaceutical company that develops antibody therapies. The company provides pipeline products such as CALY-0001 and CALY-0002. Its CALY-0001 therapeutic antibody is used in the treatment of Crohn’s disease; and CALY-0002 a humanized monoclonal antibody used in the treatment of refractory celiac disease. Its target therapy areas include gastro-intestinal diseases such as pancreatic and gastric cancer, inflammatory bowel disease. Calypso therapy areas are fibrotic diseases, metastatic cancer, Crohn’s disease and refractory celiac disease. The company develops humanized or fully human monoclonal antibodies. It partners with pharmaceutical companies. Calypso is headquartered in Geneva, Switzerland.
For a complete picture of CALY-002’s drug-specific PTSR and LoA scores, buy the report here.